Next-generation sequencing (NGS) technology has advanced our understanding of the
human microbiome by allowing for the discovery and characterization of unculturable …

Antibiotic-mediated perturbation of the gut microbiome is associated with numerous
infectious and autoimmune diseases of the gastrointestinal tract. Yet, as the gut microbiome …

Previous studies have suggested that the gut microbiome influences the response to
checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial …

Symbiotic microorganisms inhabiting the gastrointestinal tract promote health by decreasing
susceptibility to infection and enhancing resistance to a range of diseases. In this Review …

The gut microbiota have long been recognized to play a key role in human health and
disease. Currently, several lines of evidence from preclinical to clinical research have …

Background Current therapies for recurrent Clostridioides difficile infection do not address
the disrupted microbiome, which supports C. difficile spore germination into toxin-producing …

Abstract Scope In 2009, the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) published the first treatment guidance document for Clostridioides …

The trillions of microorganisms in the human intestine are important regulators of health, and
disruptions in the gut microbial communities can cause disease. The gut, liver and immune …

This clinical practice guideline is a focused update on management of Clostridioides difficile
infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for …

Abstract Background Recurrent Clostridioides difficile infection, associated with dysbiosis of
gut microbiota, has substantial disease burden in the USA. RBX2660 is a live biotherapeutic …